Cytovia Therapeutics and Cellectis, a clinical stage cell therapy company announced a $760 million research and development collaboration to develop TALEN gene edited …
Risk and reward are two of the most commonly used words in investing. The two are symbiotic and complement each other perfectly.
Unphased by some risk? If the answer is yes, then biotech stocks might be the way to go.
Piper Jeffery analyst Joshua Schimmer is weighing in on the biotechnology company bluebird bio Inc (NASDAQ:BLUE) and French genome engineering company Cellectis SA (ADR) (NASDAQ:CLLS), as shares …
